{"id":"breast-cancer-cohort","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Muscle pain"}]},"_chembl":{"chemblId":"CHEMBL4594615","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The drug works by binding to the HER2 protein on the surface of cancer cells, which can lead to the inhibition of cancer cell growth and proliferation. This can help to slow or stop the growth of breast cancer tumors.","oneSentence":"This drug targets the HER2 protein to inhibit cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:59.531Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of HER2-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT06635447","phase":"PHASE3","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-26","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT07424547","phase":"PHASE1","title":"Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2026-03-03","conditions":"Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer","enrollment":386},{"nctId":"NCT03030404","phase":"","title":"Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Stomach Neoplasms, Stomach Cancer, Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS)","enrollment":733},{"nctId":"NCT07498413","phase":"","title":"Epidemiology and Treatment of HR+/HER2- Breast Cancer in England","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-06-08","conditions":"Breast Cancer","enrollment":218677},{"nctId":"NCT07494448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":"HER 2 Positive Advanced Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT04482309","phase":"PHASE2","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer","enrollment":477},{"nctId":"NCT07287098","phase":"PHASE2","title":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-05","conditions":"Breast Neoplasms","enrollment":600},{"nctId":"NCT06994377","phase":"","title":"Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-06-25","conditions":"Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT07360314","phase":"PHASE1","title":"Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2026-02-13","conditions":"Advanced Solid Tumors","enrollment":138},{"nctId":"NCT06465069","phase":"PHASE1","title":"A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-07-01","conditions":"Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor","enrollment":420},{"nctId":"NCT07491055","phase":"","title":"Wide-Angle Tomosynthesis and AI in Diagnostic Mammography","status":"NOT_YET_RECRUITING","sponsor":"Jean Seely","startDate":"2026-04-01","conditions":"Breast Neoplasms Diagnosis, Brest Cancer","enrollment":1400},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":"Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":392},{"nctId":"NCT07488676","phase":"PHASE1, PHASE2","title":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-03-31","conditions":"Gastric or Gastro-esophageal Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":150},{"nctId":"NCT05277051","phase":"PHASE1","title":"First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Neoplasms","enrollment":152},{"nctId":"NCT05963997","phase":"PHASE1, PHASE2","title":"A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2023-10-09","conditions":"Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer","enrollment":49},{"nctId":"NCT05612048","phase":"NA","title":"A Study of Tooth Erosion in People With Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-11-03","conditions":"Esophagogastric Cancer","enrollment":174},{"nctId":"NCT06827236","phase":"PHASE1, PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":"Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer","enrollment":380},{"nctId":"NCT00469339","phase":"","title":"Risk Communication Within Mexican-American Families","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2007-04-27","conditions":"Breast Cancer, Diabetes, Colon Cancer","enrollment":498},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT05283330","phase":"PHASE1","title":"Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors","status":"RECRUITING","sponsor":"Orano Med LLC","startDate":"2022-12-22","conditions":"Cervical Cancer, Breast Cancer, Colon Cancer","enrollment":48},{"nctId":"NCT06188559","phase":"PHASE2","title":"A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-04-10","conditions":"Breast Cancer","enrollment":135},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT05537740","phase":"PHASE1","title":"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-10-11","conditions":"Advanced Solid Tumors","enrollment":129},{"nctId":"NCT00475761","phase":"","title":"Breast Mammogram and Tissue Study","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-05-11","conditions":"Breast Neoplasms","enrollment":466},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT06966453","phase":"PHASE1, PHASE2","title":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-06-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":100},{"nctId":"NCT07101081","phase":"","title":"GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-04-01","conditions":"Gynaecological Cancers","enrollment":350},{"nctId":"NCT07394387","phase":"PHASE2","title":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-01","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":39},{"nctId":"NCT06417801","phase":"","title":"Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-06-17","conditions":"Metastatic Breast Cancer","enrollment":70},{"nctId":"NCT06120283","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-12-01","conditions":"Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT04443088","phase":"PHASE1","title":"An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","startDate":"2020-06-26","conditions":"Cancer, Solid Tumor, Adult, Cancer Metastatic","enrollment":78},{"nctId":"NCT07478900","phase":"NA","title":"Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2025-09-10","conditions":"Breast Cancer (Locally Advanced or Metastatic), Tattoo Skin Markers, Neoadjuvant Chemoimmunotherapy","enrollment":30},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT04536584","phase":"NA","title":"Impact of Personalized and Remote Support Centered on Exercise and Physical Activity for Breast Cancer Patients","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2020-12-18","conditions":"Breast Cancer Female","enrollment":824},{"nctId":"NCT05007379","phase":"","title":"Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2021-11-02","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07478016","phase":"","title":"EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2022-12-21","conditions":"Breast Cancer, Ductal Carcinoma In Situ","enrollment":200},{"nctId":"NCT05656131","phase":"PHASE2","title":"Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer","status":"SUSPENDED","sponsor":"wang shusen","startDate":"2022-11-23","conditions":"Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer","enrollment":80},{"nctId":"NCT04653740","phase":"NA","title":"Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2020-09-08","conditions":"Advanced Breast Cancer","enrollment":25},{"nctId":"NCT05964504","phase":"","title":"Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-12-20","conditions":"Metastatic Breast Cancer, Lobular Breast Carcinoma","enrollment":12},{"nctId":"NCT05340413","phase":"PHASE2","title":"Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-03-25","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":65},{"nctId":"NCT07472803","phase":"","title":"Longitudinal Body Composition Assessment in Breast Cancer Patients","status":"RECRUITING","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2025-05-19","conditions":"Breast Neoplasms, Body Composition, Sarcopenia","enrollment":100},{"nctId":"NCT05230810","phase":"PHASE1, PHASE2","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Criterium, Inc.","startDate":"2022-08-25","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT04802759","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-22","conditions":"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer","enrollment":316},{"nctId":"NCT04300556","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","status":"RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-08-06","conditions":"Solid Tumor","enrollment":182},{"nctId":"NCT06332508","phase":"PHASE1","title":"Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2022-12-30","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT05957536","phase":"PHASE1","title":"A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors","status":"RECRUITING","sponsor":"D3 Bio (Wuxi) Co., Ltd","startDate":"2023-09-19","conditions":"HER-2 Positive Advanced Solid Tumors","enrollment":128},{"nctId":"NCT06745804","phase":"PHASE1","title":"Study of 68Ga-R10602","status":"RECRUITING","sponsor":"Radionetics Oncology","startDate":"2024-12-10","conditions":"Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma","enrollment":36},{"nctId":"NCT07469709","phase":"","title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","status":"RECRUITING","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2024-02-01","conditions":"Breast Cancer, Colo-rectal Cancer, Ovarian Cancer","enrollment":850},{"nctId":"NCT06053086","phase":"NA","title":"SAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2025-03-01","conditions":"Breast Cancer","enrollment":500},{"nctId":"NCT04585750","phase":"PHASE1, PHASE2","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2020-10-29","conditions":"Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer","enrollment":300},{"nctId":"NCT05865990","phase":"PHASE2","title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-11-24","conditions":"Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult","enrollment":63},{"nctId":"NCT07287917","phase":"PHASE1, PHASE2","title":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Aminex Therapeutics, Inc.","startDate":"2026-01-26","conditions":"Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer","enrollment":92},{"nctId":"NCT05417594","phase":"PHASE1, PHASE2","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-24","conditions":"Advanced Solid Malignancies","enrollment":695},{"nctId":"NCT06382818","phase":"NA","title":"Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2025-03-06","conditions":"Breast Cancer","enrollment":854},{"nctId":"NCT01603316","phase":"PHASE2","title":"Food: A Three-Arm Study Examining Food Insecurity Interventions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-05-08","conditions":"Cancer Patients","enrollment":606},{"nctId":"NCT02896335","phase":"PHASE2","title":"Palbociclib and Pembrolizumab In Central Nervous System Metastases","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-02-02","conditions":"Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases","enrollment":45},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT05460273","phase":"PHASE1, PHASE2","title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-07-11","conditions":"Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer","enrollment":119},{"nctId":"NCT05926024","phase":"","title":"Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-01-06","conditions":"Breast Cancer","enrollment":253},{"nctId":"NCT06229392","phase":"PHASE1","title":"A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2026-06-01","conditions":"Breast Cancer, Breast Cancer Triple Negative","enrollment":""},{"nctId":"NCT07465172","phase":"NA","title":"GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Breast Cancer Trials, Australia and New Zealand","startDate":"2026-03","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT05810870","phase":"PHASE2","title":"PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-05-24","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":14},{"nctId":"NCT07229313","phase":"PHASE1","title":"A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Kivu Bioscience Inc.","startDate":"2025-11-13","conditions":"Advance Solid Tumors","enrollment":76},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT03619083","phase":"","title":"Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-13","conditions":"Breast Cancer","enrollment":187},{"nctId":"NCT06533059","phase":"PHASE1","title":"A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors","status":"RECRUITING","sponsor":"Alterome Therapeutics, Inc.","startDate":"2024-08-22","conditions":"Cancer, Breast Cancer, Endometrial Cancer","enrollment":110},{"nctId":"NCT02945579","phase":"NA","title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-01-20","conditions":"Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative","enrollment":120},{"nctId":"NCT04332653","phase":"PHASE1, PHASE2","title":"NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"NeoImmuneTech","startDate":"2020-06-10","conditions":"Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer","enrollment":215},{"nctId":"NCT04723810","phase":"PHASE1, PHASE2","title":"TumorGlow Intraoperative Molecular Imaging (IMI)","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-08-14","conditions":"Tumor, Solid","enrollment":500},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":40},{"nctId":"NCT06274515","phase":"PHASE4","title":"A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-04-02","conditions":"Breast Cancer","enrollment":320},{"nctId":"NCT01334021","phase":"PHASE2","title":"Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-05-31","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":1100},{"nctId":"NCT05877599","phase":"PHASE1","title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-12","conditions":"Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma","enrollment":46},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT05056207","phase":"NA","title":"PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-11-17","conditions":"Lymphedema","enrollment":260},{"nctId":"NCT07076485","phase":"PHASE2","title":"Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-08-19","conditions":"Breast Cancer","enrollment":768},{"nctId":"NCT07136493","phase":"NA","title":"Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2026-05-12","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":350},{"nctId":"NCT06257264","phase":"PHASE1","title":"A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-03-11","conditions":"Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer","enrollment":258},{"nctId":"NCT07214662","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2026-01-13","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT07211178","phase":"","title":"Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies","status":"RECRUITING","sponsor":"Tempus AI","startDate":"2025-10-27","conditions":"Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":900},{"nctId":"NCT01788839","phase":"","title":"Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-02","conditions":"Breast Cancer, Lymphoma, Hodgkin's Lymphoma","enrollment":475},{"nctId":"NCT06315205","phase":"PHASE1","title":"Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2023-07-26","conditions":"Healthy","enrollment":90},{"nctId":"NCT06806930","phase":"PHASE2","title":"Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)","status":"RECRUITING","sponsor":"George Washington University","startDate":"2024-10-01","conditions":"Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III","enrollment":90},{"nctId":"NCT05554354","phase":"PHASE2","title":"Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":1},{"nctId":"NCT07276880","phase":"PHASE2","title":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-03","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT06545331","phase":"PHASE1","title":"Study of XB010 in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2024-08-06","conditions":"Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer","enrollment":396},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT05573893","phase":"","title":"PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-12","conditions":"Breast Neoplasms, Breast Cancer, Neoplasm Metastasis","enrollment":800},{"nctId":"NCT05377684","phase":"","title":"Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2022-06-09","conditions":"Early-stage Breast Cancer","enrollment":450},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT04336241","phase":"PHASE1","title":"Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Replimune Inc.","startDate":"2019-10-17","conditions":"Cancer","enrollment":36},{"nctId":"NCT06449222","phase":"PHASE2","title":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-26","conditions":"Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers","enrollment":83},{"nctId":"NCT02778685","phase":"PHASE2","title":"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2016-09-30","conditions":"Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7","enrollment":47},{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":"Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8","enrollment":17},{"nctId":"NCT07408089","phase":"PHASE1","title":"Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Boundless Bio, Inc.","startDate":"2026-02-25","conditions":"Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":96},{"nctId":"NCT05523947","phase":"PHASE1, PHASE2","title":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","status":"RECRUITING","sponsor":"Yuhan Corporation","startDate":"2022-08-26","conditions":"HER2-Positive Solid Tumor","enrollment":147},{"nctId":"NCT07190469","phase":"PHASE1","title":"PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"ProteinQure Inc.","startDate":"2025-09-16","conditions":"Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer","enrollment":80},{"nctId":"NCT06878248","phase":"PHASE1","title":"A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Calibr, a division of Scripps Research","startDate":"2025-04-17","conditions":"Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":554,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Breast cancer cohort","genericName":"Breast cancer cohort","companyName":"Centre Leon Berard","companyId":"centre-leon-berard","modality":"Biologic","firstApprovalDate":"","aiSummary":"This drug targets the HER2 protein to inhibit cancer cell growth. Used for Adjuvant treatment of HER2-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}